HR0334 LRB094 12034 CSA 45174 r

1
HOUSE RESOLUTION

 
2     WHEREAS, Ovarian cancer is the leading cause of death from
3 gynecologic cancers in the United States, and the fifth leading
4 cause of death among U.S. women; and
 
5     WHEREAS, It is one of the most insidious types of cancer
6 affecting women of which has few signs or symptoms and is
7 difficult to detect; and
 
8     WHEREAS, Ovarian cancer symptoms included bloating,
9 frequent urination, constipation, diarrhea, and fatigue; any
10 woman who experiences these symptoms for more than two to three
11 weeks should promptly have a thorough examination to determine
12 if ovarian cancer is present; and
 
13     WHEREAS, Increased awareness of the symptoms and risk
14 factors of ovarian cancer will enhance chances of early
15 detection and survival from the disease; and
 
16     WHEREAS, Prostate cancer is the most commonly diagnosed
17 non-skin cancer and the second leading cause of cancer-related
18 death among men; and
 
19     WHEREAS, Prostate cancer has accounted for 15 percent of
20 the nation's cancer burden and 15 percent of male cancer
21 deaths; and
 
22     WHEREAS, Research suggests that men can reduce their risk
23 of prostate cancer mortality if they follow recommended
24 prostate cancer screening guidelines; and
 
25     WHEREAS, Increased awareness and use of early detection
26 practices by men is essential to controlling prostate cancer;
27 therefore, be it
 

 

 

HR0334 - 2 - LRB094 12034 CSA 45174 r

1     RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE
2 NINETY-FOURTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that
3 we designate the month of September 2005 as Ovarian and
4 Prostate Cancer Awareness Month, to be observed throughout the
5 State as a month set apart to promote advocacy activities, to
6 call attention to ovarian cancer and prostate cancer research,
7 and to honor those whose lives have been impacted by these
8 cancers; and be it further
 
9     RESOLVED, That we call upon the citizens of the State to
10 promote awareness of ovarian and prostate cancer.